Search Orphan Drug Designations and Approvals
-
Generic Name: | (R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide |
---|---|
Date Designated: | 07/03/2003 |
Orphan Designation: | Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati, Ohio 45219 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-